ArticleFrontiers in surgery2026
Impact of RAS mutation status on early progression in patients with initially unresectable colorectal liver metastases undergoing conversion therapy: a retrospective analysis.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer liver metastases (CRLM) frequently recur or progress after systemic and local treatment, particularly in patients with initially unresectable disease. RAS mutations are associated with poor outcomes in CRLM, but their relationship with early progression or recurrence after conversion therapy remains unclear. This study evaluated the prognostic impact of RAS mutation status in patients with initially unresectable CRLM (IU-CRLM) undergoing conversion therapy. Methods: This retrospective cohort study included 194 patients with initially unresectable, pMMR CRLM treated at Sun Yat-sen University Cancer Center between December 2012 and January 2020. Early progression/recurrence was defined as disease progression after failed conversion, recurrence after successful conversion, or death within six months. Event-free survival (EFS) and overall survival (OS) were analyzed according to RAS status. Results: Of 194 patients, 87 (44.8%) achieved successful conversion and 51 (26.3%) harbored RAS mutations. RAS-mutant patients had a higher early progression/recurrence rate than RAS wild-type patients (41.2% vs. 19.6%, Conclusions: RAS mutation is associated with a higher risk of early progression/recurrence in patients with IU-CRLM undergoing conversion therapy, particularly among those who fail to achieve successful conversion. These findings may support individualized surveillance and treatment strategies for RAS-mutant IU-CRLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.